Edition:
United States

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

30.05USD
12 Dec 2017
Change (% chg)

$0.45 (+1.52%)
Prev Close
$29.60
Open
$29.55
Day's High
$30.37
Day's Low
$29.54
Volume
57,282
Avg. Vol
47,803
52-wk High
$34.02
52-wk Low
$26.43

Select another date:

Wed, Dec 6 2017

BRIEF-Genomic Health Announces Research Collaboration with Janssen Pharma

* GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT

BRIEF-Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

* GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS

BRIEF-Genomic Health Q3 loss per share $0.06

* Genomic Health announces third quarter 2017 financial results and reports recent business progress

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

BRIEF-Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test

* Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test Source text for Eikon: Further company coverage:

BRIEF-Genomic Health Q2 loss per share $0.08

* Genomic Health announces second quarter 2017 financial results and reports recent business progress

Select another date: